March 2019 Midatech Pharma PLC ("Midatech" or the "Company") ADR Ratio Change Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, ann

("Midatech" or the "Company")

Midatech Pharma (AIM: MTPH; Nasdaq: MTP),

the R&D company focused on delivering innovative oncology and rare disease products to patients, announces a ratio change on

its American Depositary Receipts ("ADR") from one (1) ADR representing two (2) ordinary shares, to the new ratio of one

(1) ADR representing twenty (20) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected

Pursuant to the Ratio Change, effective

8 April 2019, ADR holders will be required on a mandatory basis to surrender their ADRs for cancellation and exchange to receive

(1) new ADRs (New CUSIP: 59564R203) for every ten (10) old ADRs (Old CUSIP: 59564R104). No fractional ADRs will be allocated. The

aggregate fractions, if any, will be sold and the net proceeds will be distributed to the entitled DR holder. The Company's

Depositary, Deutsche Bank Trust Company Americas, will contact DR holders and arrange for the exchange of their existing ADRs for

For ADR holders, the Ratio Change will

have the same effect as a one-for-10 reverse ADR split. The ordinary shares of Midatech will not be affected by this change.

The Ratio Change is aimed to bring the

price of the Company's ADRs into compliance with the Nasdaq $1.00 minimum bid price per share requirement, though Midatech

can give no assurance that the Ratio Change will be effective in achieving this goal.

The number of ADRs in issue on 18 March

For further information, please contact:

Panmure Gordon (UK) Limited (NOMAD)

Consilium Strategic Communications

About Midatech Pharma PLC

Midatech Pharma (LSE AIM: MTPH; NASDAQ:

MTP) is an R&D company focused on delivering innovative oncology and rare disease products to patients. The Company is developing

a range of improved chemo-therapeutics or new immuno-therapeutics, using its three-proprietary platform drug delivery technologies,

all of which are in the clinic, specifically:

Each of our three technologies are thus

focussed on improved bio-delivery and bio-distribution of medicines or agents to areas of the body where they are needed and can

exert their actions in an effective, safe and precise manner.

Midatech is headquartered in Oxfordshire,

with an R&D facility in Cardiff and a manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com.

Forward-Looking Statements

Certain statements in this press release

may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States.

Such forward-looking statements include, but are not limited to, statements expressed or implied regarding our ability to regain

compliance with NASDAQ's minimum bid share price requirement. Any forward-looking statements are based on currently available

competitive, financial and economic data together with management's views and assumptions regarding future events and business

performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there

are some known and unknown factors that could cause actual results to differ materially from any future results, performance or

achievements expressed or implied by such forward-looking statements.

Reference should be made to those documents

that we shall file from time to time or announcements that may be made by the Company in accordance with the London Stock Exchange

AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations

promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause

actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking

statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning

the Company are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM

Rules or the DTRs or by relevant law in the United Kingdom or the United States, we do not undertake any obligation to publicly

update or revise any forward-looking statements because of new information, future events or otherwise arising.